Shares of Endologix, Inc. (NASDAQ:ELGX) have been assigned an average recommendation of “Hold” from the nine analysts that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $2.90.
Several equities research analysts have recently issued reports on ELGX shares. BTIG Research lowered their price objective on shares of Endologix to $4.00 and set a “buy” rating for the company in a research report on Thursday, August 23rd. Zacks Investment Research cut shares of Endologix from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. BidaskClub cut shares of Endologix from a “hold” rating to a “sell” rating in a report on Friday, August 17th. Piper Jaffray Companies reduced their target price on shares of Endologix to $3.00 and set a “neutral” rating for the company in a report on Wednesday, October 3rd. Finally, Oppenheimer set a $3.00 target price on shares of Endologix and gave the stock a “hold” rating in a report on Friday, November 2nd.
Shares of ELGX stock opened at $0.71 on Monday. The company has a quick ratio of 0.96, a current ratio of 1.55 and a debt-to-equity ratio of 4.38. Endologix has a 12-month low of $0.67 and a 12-month high of $6.72. The firm has a market cap of $73.42 million, a PE ratio of -1.48 and a beta of 0.37.
Institutional investors and hedge funds have recently made changes to their positions in the stock. MetLife Investment Advisors LLC boosted its holdings in Endologix by 128.2% during the second quarter. MetLife Investment Advisors LLC now owns 41,313 shares of the medical instruments supplier’s stock worth $234,000 after purchasing an additional 23,210 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Endologix by 13.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 429,969 shares of the medical instruments supplier’s stock worth $2,434,000 after purchasing an additional 49,321 shares during the last quarter. Engineers Gate Manager LP acquired a new position in Endologix during the second quarter worth $442,000. BlackRock Inc. boosted its holdings in Endologix by 11.1% during the second quarter. BlackRock Inc. now owns 5,644,438 shares of the medical instruments supplier’s stock worth $31,948,000 after purchasing an additional 565,175 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Endologix in the third quarter valued at $238,000. Institutional investors and hedge funds own 73.96% of the company’s stock.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.